Cas:141321-53-1 N-t-BOC-D-Isoleucinol manufacturer & supplier

We serve Chemical Name:N-t-BOC-D-Isoleucinol CAS:141321-53-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

N-t-BOC-D-Isoleucinol

Chemical Name:N-t-BOC-D-Isoleucinol
CAS.NO:141321-53-1
Synonyms:N-Boc-L-isoleucinol;Boc-L-Ile-ol;BOC-D-ISOLEUCINOL;N-tert-butyloxycarbonyl-L-isoleucinol
Molecular Formula:C11H23NO3
Molecular Weight:217.30500
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:319.3ºC at 760 mmHg
Density:0.984g/cm3
Index of Refraction:1.454
PSA:58.56000
Exact Mass:217.16800
LogP:2.30900

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like N-Boc-L-isoleucinol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-tert-butyloxycarbonyl-L-isoleucinol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Boc-L-isoleucinol Use and application,BOC-D-ISOLEUCINOL technical grade,usp/ep/jp grade.


Related News: While they are early data, “it’s also very reassuring that those patients who have progressed can be rather easily reinduced into remission,” Tendler said. J&J and AbbVie are now taking the same approach for the GLOW study, he added. N-t-BOC-D-Isoleucinol manufacturer f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. N-t-BOC-D-Isoleucinol supplier AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. N-t-BOC-D-Isoleucinol vendor Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). N-t-BOC-D-Isoleucinol factory AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer.